{"groups":[{"description":"Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.\n\nSVd (Selinexor+Bortezomib+dexamethasone): Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)","id":"FG000","title":"SVd (Selinexor+Bortezomib+Dexamethasone)"},{"description":"Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.\n\nVd (Bortezomib+dexamethasone): Vd Arm (\\~50): Bortezomib (Cycles 1-8 \\[BIW\\], Cycles ≥ 9 \\[QW\\]) + dexamethasone (Cycles 1-8 \\[Four times a week\\], Cycles ≥ 9 \\[BIW\\])","id":"FG001","title":"Vd (Bortezomib+Dexamethasone)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"101"},{"groupId":"FG001","numSubjects":"53"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"100"},{"groupId":"FG001","numSubjects":"52"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}